Plasma cell neoplasms (PCNs) are lymphoproliferative disorders arising from post germinal center B cells with somatic hypermutations that exhibit varied manifestations and can be a challenging diagnosis for clinicians and pathologists. A subset of PCN reveals translocations of chromosome 14 involving the immunoglobulin heavy chain locus (IgH) with specific clinicopathological features with prognostic implications that have not been well characterized. We present to you the case of a 69-year-old man with mid back pain that radiated to his chest. Imaging of the thoracic spine revealed heterogeneous enhancement of both T6 and T11 vertebrae, after which he underwent a CT-guided biopsy of the T6 vertebra. The touch preparation and core biopsy revealed extensive infiltration by small-sized plasmacytic cells in a paratrabecular pattern. Immunohistochemistry revealed these cells to be positive for CD138, CD20, Bcl-2, MUM1, and cyclin D1, and negative for CD45, CD3, CD5, CD10, and Bcl-6. In situ hybridization (ISH) for kappa and lambda demonstrated lambda light chain restriction leading to a diagnosis of plasmacytic neoplasm with features most consistent with a CD20-positive plasmacytoma/myeloma. Fluorescence ISH revealed polysomy of odd-numbered chromosomes, chromosome 17 abnormalities, and the CCND1/IGH fusion gene in 71% of the examined cells. Although CD20 positivity in PCN with t(11,14) is well documented and has considerable therapeutic implications, it becomes very difficult to distinguish the present case from a B-cell lymphoma with plasmacytic features. Some studies show a worse prognosis for translocation-associated PCN, while other studies do not support this finding. Since PCNs present with heterogeneous morphology, clinical features, and immunohistochemical and molecular profiles, extensive work-up and clinicopathologic correlation is essential for appropriate classification and management.
Anaplastic Multiple Myeloma (AMM) With Aberrant Myeloid Antigen Expression
Reem Alrabeh, April Ewton, MD; Houston Methodist, Houston, TX Introduction: Anaplastic multiple myeloma (AMM) is a rare variant of multiple myeloma with an aggressive clinical course. Studies have suggested that this variant is a form of aggressive transformation or a clonal evolution of the initial plasma cell clone. Prognosis is often poor with extramedullary involvement and resistance to novel myeloma chemotherapy. Case Presentation: A 71-year-old Caucasian woman presented to the hospital with fatigue and shortness of breath. She reports having a history of multiple myeloma for 17 years. She was found to have pancytopenia (WBC 3.07 k/uL, Hgb 8.8 g/dL, platelets 56 k/uL). Ancillary work-up included a skeletal survey, which showed numerous lytic lesions throughout the calvarium and a high serum-free kappa/lambda light chain ratio of 197.59 mg/dL (0.26-1.65). However, serum electrophoresis did not display any monoclonal bands. Bone marrow aspirate and biopsy revealed a plasma cell myeloma with anaplastic features, involving 75% of marrow cellularity. The plasma cells were atypical, enlarged, and multinucleated (megakaryocyte-like). They were strongly positive for CD138 and variably positive for CD20 by immunohistochemistry. Kappa and lambda in situ hybridization demonstrated kappa light chain restriction. Corresponding flow cytometry detected 64% plasma cells positive for CD45 (dim), CD19 (subset), CD20 (variable), CD38, CD138, CD71, CD117, CD15 (subset), CD33 (subset), and kappa. They were negative for CD56 and lambda. Karyotype was 46XX. She was initially treated with Melphalan and Lenalidomide but did not undergo autologous hematopoietic stem cell transplant (HSCT). She had a slow decline over the next 2 years. She eventually presented with L2 spinal cord compression and died shortly thereafter. Conclusion: AMM can propose a diagnostic challenge due to variable morphologic appearance. Furthermore, this case represents an unusual form of anaplastic myeloma with expression of CD15/CD33. Myeloid antigen expression by malignant plasma cells is uncommon but often associated with a poorer outcome.
188

A Case of Hairy Cell Leukemia Uncharacteristically Presents With Absolute Monocytosis as a Manifestation of a Concurrent Myelodysplastic/Myeloproliferative Neoplasm
Todd Williams, MD, Lindsay Taute, MD, Jennifer Dunlap, MD, Guang Fan; Oregon Health and Sciences University, Portland
A 77-year-old man with no disclosed hematologic abnormalities presents with splenomegaly, lymphadenopathy, and weight loss. CBC reveals absolute monocytosis, mild normocytic anemia, and thrombocytopenia, and is otherwise normal. A peripheral blood smear shows a marked abundance of monocytes, immature monocytes, dysplastic neutrophils, dysplastic erythrocytes, and a population of lymphocytes with morphologic features consistent with hairy cell lymphocytes. Flow cytometry on the peripheral blood reveals two distinct cell populations within the monocyte gate. One population shows a characteristic monocytic immunophenotype, and the other population expresses immunophenotypic markers consistent with hairy cell lymphocytes. A bone marrow biopsy reveals diffuse infiltration and replacement by hairy cell leukemia and minimal fibrosis. The overriding presence of hairy cell leukemia obscures the ability to evaluate for myelodysplastic/myeloproliferative histologic alterations. Genetic studies performed on the peripheral blood reveal BRAF V600E and KRAS p.G12D mutations. Hairy cell leukemia characteristically presents with monocytopenia. The unusual presence of monocytosis, the myelodysplastic findings in the peripheral blood, and KRAS mutations raise suspicion for a concurrent myelodysplastic/myeloproliferative neoplasm, likely chronic myelomonocytic leukemia or atypical chronic myelogenous leukemia. It is not unusual for a concurrent malignancy to coexist with hairy cell leukemia as multiple sources have shown that the rate of additional malignancy in hairy cell leukemia is significantly increased compared to the general population. The diagnosis of a concurrent myelodysplastic/myeloproliferative neoplasm could not be definitively made because the prevailing presence of hairy cell leukemia obscures any myeloid abnormalities that may be present in the bone marrow histology. Myeloproliferative neoplasms constitute a heterogeneous group of clonal cell disorders demonstrating proliferation of one or more blood cell lines and giving rise to mature, but variably functional cells. Primary myelofibrosis (PMF) is characterized by progressive fibrosis of the bone marrow cavity and initial proliferation of granulocytes and megakaryocytes with inevitable evolution to bone marrow failure, peripheral blood cytopenias, and extramedullary hematopoiesis. Though platelet counts in PMF early in the course of the disease may be normal or increased, megakaryocyte development programs are impaired, often resulting in varying degrees of platelet dysfunction. Hematopoietic stem cell transplantation
